Insider trading disclosure:CRISPR Therapeutics Directors, officers net sell 2. 72 million shares
insider trading disclosure:CRISPR Therapeutics Directors, officers net sell 2. 72 million shares
[unable to retrieve full-text content]
Flush financial
2020 06 Months 25 days 07:11
2020 年 6 月 24th,CRISPR Therapeutics(stock code:CRSP)announcement disclosure of corporate insider trading:the company’s Directors, executives Bolzon Bradley J PhD, Ho, Tony W in 2020 6 October, from 22 to 2020 6 May 23,…
Baidu snapshot
Published at Tue, 26 Jun 2020 20:26:18 +0000
- CRISPR rivals put patents aside to help in fight against Covid-19 – STAT
- CRISPR 2.0: Base Editing in the Groove – Genetic Engineering & Biotechnology News
- The Promises of CRISPR Genome Editing in Biomedicine – Labiotech.eu
- The Code Breaker and Crispr People — the ethics of editing humanity – Financial Times
- ERS Genomics Licenses CRISPR Patents to CRO ZeClinics – GenomeWeb
- The Dark Side of CRISPR – Scientific American
- ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement – BioSpace
- Scientists Use CRISPR To Create Model of AML Progression – AJMC.com Managed Markets Network
- DECODR app identifies DNA mutations from CRISPR gene therapies – European Pharmaceutical Review
- CRISPR/Cas technology as a promising weapon to combat viral infections – Wiley
- Neanderthal-like ‘mini-brains’ created in lab with CRISPR – Nature.com
- Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair – Phys.org
- Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair – EurekAlert
- New CRISPR tech targets human genome’s complex code: Programmable CRISPR/Cas9-based kinase offers insights into, control over regulatory histone proteins – Science Daily
- After ditching Editas, AbbVie taps Caribou for new CRISPR, CAR-T pact – FierceBiotech
